Back to mobile site

H.C. Wainwright Reiterates Buy Rating on ORIC Pharmaceuticals (ORIC)

April 2, 2026 6:45 AM EDT Send to a Friend
H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $25.00 price target on ORIC Pharmaceuticals (NASDAQ: ORIC).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login